Prenetics Global (NASDAQ:PRE – Get Free Report) and Bio-Rad Laboratories (NYSE:BIO.B – Get Free Report) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings.
Profitability
This table compares Prenetics Global and Bio-Rad Laboratories’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Prenetics Global | -229.17% | -15.70% | -12.98% |
| Bio-Rad Laboratories | -30.18% | 3.74% | 2.65% |
Valuation and Earnings
This table compares Prenetics Global and Bio-Rad Laboratories”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Prenetics Global | $21.74 million | 1.86 | -$62.72 million | ($3.23) | -1.37 |
| Bio-Rad Laboratories | $2.67 billion | 3.90 | -$637.32 million | ($27.33) | -13.66 |
Risk and Volatility
Prenetics Global has a beta of -0.2, meaning that its stock price is 120% less volatile than the S&P 500. Comparatively, Bio-Rad Laboratories has a beta of 0.73, meaning that its stock price is 27% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of current recommendations and price targets for Prenetics Global and Bio-Rad Laboratories, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Prenetics Global | 0 | 0 | 1 | 0 | 3.00 |
| Bio-Rad Laboratories | 0 | 0 | 0 | 0 | N/A |
Prenetics Global presently has a consensus target price of $9.00, indicating a potential upside of 103.16%. Given Prenetics Global’s higher possible upside, equities research analysts plainly believe Prenetics Global is more favorable than Bio-Rad Laboratories.
Insider & Institutional Ownership
25.0% of Prenetics Global shares are held by institutional investors. Comparatively, 0.0% of Bio-Rad Laboratories shares are held by institutional investors. 28.4% of Bio-Rad Laboratories shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summary
Bio-Rad Laboratories beats Prenetics Global on 7 of the 13 factors compared between the two stocks.
About Prenetics Global
Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies. In addition, the company, through its equity interests in ACT Genomics Holdings Company Limited, is involved in genomic profiling of solid tumors through ACTOnco. Prenetics Global Limited was founded in 2007 and is based in Quarry Bay, Hong Kong.
About Bio-Rad Laboratories
Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. In addition, the company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
Receive News & Ratings for Prenetics Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prenetics Global and related companies with MarketBeat.com's FREE daily email newsletter.
